Vaccine Info

Sputnik V Vaccine

Last Reviewed
January 16, 2021

Sputnik V Vaccine Description

The COVID-19 vaccine Sputnik V (Gam-COVID-Vac) is an adenoviral-based vaccine against the SARS-CoV-2 coronavirus. Sputnik V uses a weakened virus to deliver small parts of a pathogen and stimulate an immune response.

It is a vector vaccine based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated. Adenovirus is used as a “container” to deliver the coronavirus gene to cells and start the synthesis of the new coronavirus's envelope proteins, “introducing” the immune system to a potential enemy.

The Sputnik V (Gam-COVID-Vac) vaccine intends to reduce the time taken for the actual development of immunity to SARS-CoV-2, the virus behind the COVID-19 pandemic.

In May 2020, a state institute, the Gamaleya National Research Centre of Epidemiology and Microbiology, announced that it had developed the vaccine, which does not have any side effects. The first vaccination leads to humoral cellular immunity, and once a second vaccine is administered, a key feature of this vaccine kicks in—memory cells are formed.

The Sputnik V vaccine was developed by the same government labs that developed what is claimed as "effective against the Ebola virus, as well as a vaccine against the MERS virus.”

On August 1, 2020, the Russian Health Minister Mikhail Murashko told reporters the 'clinical trial had been declared completed.'

The Russian Direct Investment Fund (RDIF) was announced on August 20, 2020. The Sputnik V coronavirus vaccine candidate will be tested on 40,000 volunteers in more than 45 medical centers to confirm clinical efficacy post-approval studies.

On August 20, 2020, the Russian Direct Investment Fund (RDIF) and the Gamaleya National Research Institute of Epidemiology and Microbiology launched an information section about “Sputnik V”

TASS reported on September 9, 2020, 'Russian Healthcare Minister Mikhail Murashko announced that Phase 3 of clinical trials of the Sputnik V vaccine against the novel coronavirus started in Russia.'

On October 27, 2020, RDIF announced it had submitted applications to the World Health Organization for an Emergency Use Listing and prequalification of the Sputnik V vaccine candidate. This news indicates the Russian Federation became one of the first countries in the world to apply to WHO for prequalification of its vaccine against the new SARS-CoV-2 coronavirus infection.

On November 24, 2020, positive results of the second interim analysis of Phase III data of the Sputnik V coronavirus vaccine. The evaluation of efficacy was carried out among 18,794 volunteers on the 28th day after receiving the first injection (the 7th day after receiving the second injection) of the vaccine or placebo, upon reaching the second checkpoint following the Clinical Study Protocol. Based on the analysis, the efficiency of Sputnik V was 95%.

Kirill Dmitriev, CEO of the Russian Direct Investment Fund, commented in a press release issued on December 11, 2020: 'AstraZeneca's decision to conduct a study using one of the two vectors of the Sputnik V vaccine is an important step towards joining forces in the fight against the pandemic. We welcome the beginning of a new phase of cooperation between vaccine manufacturers, intend to develop this partnership in the future, and look forward to starting co-production after the new vaccine has been demonstrated to be effective in clinical trials. We hope other vaccine manufacturers will also follow our example.'

According to the RDIF, the Sputnik V vaccine is registered in Argentina, Bolivia, Serbia, Algeria, Palestine, and Venezuela.

RDIF was established in 2011 and provided support to facilitate partnerships, including that with Gamaleya National Research Institute of Epidemiology and Microbiology and the Central Research Institute of the Radiation, Chemical, and Biological Defense Troops.

Sputnik V Vaccine Distribution Agreements

Over 30 countries had expressed interest in obtaining and/or licensing the Sputnik V vaccine, including, but not limited to, the UAE, Saudi Arabia, Indonesia, Philippines, Brazil, Mexico, and India.

Sputnik V Vaccine Indication

Russian COVID-19 Vaccine candidate (Gam-COVID-Vac) is indicated to build immunity to SARS-CoV-2, the virus which causes COVID-19 disease.

Pediatric, pregnancy, and oncology vaccine efficacy data pending.

Sputnik V is available in a lyophilized (dry) form of the vaccine that significantly facilitates the logistics of its distribution in international markets due to simplified requirements for its storage temperature (+ 2 + 8 degrees Celsius).

Sputnik V Vaccine Cost

The cost of 1-dose of the Sputnik V vaccine for international markets will be less than $10. Sputnik V is a 2-dose vaccine. Thus, it will cost less than $20 per person.

Sputnik V Vaccine News

January 15, 2021 - Hyderabad-based Dr. Reddy’s Laboratories Ltd. announced that it had received approval from the Drugs Control General of India to conduct a phase 3 clinical trial for the Sputnik V vaccine in India.

January 15, 2021 - The Russian Direct Investment Fund announced the Sputnik V vaccine registration by the Ministry of Health of the Republic of Paraguay.

January 14, 2021 - Reuters reported Russia would submit a formal application to the European Union next month to approve its Sputnik V vaccine, which treats COVID-19.

January 13, 2021 - The Russian Direct Investment Fund announced the Sputnik V's registration by the Ministry of Health of the Bolivarian Republic of Venezuela. The supplies will be secured through RDIF's international partners in India, China, South Korea, and other countries.

January 13, 2021 - The Russian Direct Investment Fund and one of Brazil's leading pharmaceutical companies, União Química, have agreed to supply 10 million doses of the Sputnik V vaccine in the first quarter 2021. The local production of Sputnik V has been launched in Brazil.

January 12, 2021 - TASS reported the Mexican Federal Commission for the Protection against Sanitary Risk might approve the emergency use of the "Sputnik V" COVID-19 vaccine this week, the country’s Deputy Minister of Health Hugo Lopez-Gatell.

January 11, 2021 - Reuters reported Mexico's Deputy Health Minister Hugo Lopez-Gatell said Mexico had reached agreements to acquire the Russian vaccine potentially. “We’re thinking that we could use up to 24 million doses of this vaccine, for 12 million people,” considering that Sputnik V vaccine requires two doses, Lopez-Gatell told a news conference.

January 11, 2021 - India - based Dr. Reddy’s Laboratories Ltd. announced that the independent Data and Safety Monitoring Board has reviewed the safety data from the phase 2 clinical trial of the Sputnik V vaccine and recommended the phase 3 recruitment and continue the clinical trial without any modifications. G V Prasad, Co-chairman and Managing Director, Dr. Reddy’s Laboratories, said in a press release, “The phase 2 study in India showed a very good safety profile. This further reinforces our confidence in Sputnik V's safety, which has now been administered to more than 1 million people in Russia and more than 300,000 people in Argentina. We are working closely towards fast-tracking the launch of the Sputnik V vaccine in India.”

January 11, 2021 - Moscow-based Russian Direct Investment Fund (RDIF) announced the Sputnik V vaccine registration against coronavirus by the Ministry of Health of Palestine. Sputnik V delivery to Palestine is planned for the first quarter of 2021, with the first batch expected to arrive within a month. Supplies of the vaccine will be facilitated by RDIF’s international partners in India, China, South Korea, and other countries.

January 11, 2021 - RT News reported, “Brazil will start production of Sputnik V on January 15, 2021." The Russian vaccine will be manufactured by the Brazilian pharmaceutical company União Química at two plants, one in Brasilia and Guarulhos. The firm has already received the cellular material to produce the vaccine from its developer, Moscow’s Gamaleya Institute.

January 10, 2021  - The Russian Direct Investment Fund (RDIF) announces the Sputnik V vaccine registration by the National Pharmaceutical Agency of the People's Democratic Republic of Algeria, which became the first African state to approve vaccines officially. Vaccine supplies to Algeria will be ensured through RDIF's international partners in India, China, South Korea, and other countries.

January 8, 2021 - Reuters reported Brazil's Uniao Quimica plans to produce up to 8 million vaccine doses a month.

January 8, 2021 - A New York Times reporter juggled fears engendered by the Sputnik V vaccine's politicized rollout with the urge to gain protection from the deadly virus.

January 8, 2021 - Bloomberg article: Sputnik V has one key, clever difference from the Astra and J&J vaccines: It uses the same adenovirus as J&J for the first dose (adenovirus-26) and a different adenovirus (adenovirus-5) for the second dose. In this way, it avoids the possibility of immunity to the first dose impacting the second dose's ability to work efficiently. One issue is that a large percentage of people have pre-existing immunity to adenovirus-5, but that’s not a huge drawback if the efficacy is very high.

January 6, 2021 - The Russian Direct Investment Fund and the Government of Serbia announce an agreement to supply the country with 2 million doses of Sputnik V vaccine. The first batch of the vaccine was delivered to Serbia on December 30, 2020. The vaccine was approved without additional clinical trials in the country.

January 6, 2021 - The Russian Direct Investment Fund announced the Sputnik V vaccine registration by the State Agency for Medicines and Health Technologies (Agencia Estatal De Medicamentos Y Tecnologías En Salud, AGEMED) of the Plurinational State of Bolivia.

January 6, 2021 - Ukrainian pharmaceutical firm Biolik said in a statement on its website it had applied to register Gam-COVID-Vac, also known as Sputnik V, in Ukraine.

January 2, 2021 - Russia's Minister of Health Mikhail Murashko told reporters on Saturday. "Taking into account all data, more than 800,000 people have been vaccinated," he said. Murashko stressed that vaccination is in progress among Russian citizens over 60 years old, reported TASS.

December 31, 2020 - Algeria announced it would use the Russian Sputnik V coronavirus vaccine for mass vaccinations for its population scheduled for January 2021, TSA news portal reports, citing the decision made by the Algerian government following a meeting on Wednesday chaired by Prime Minister Abdelaziz Djerad.

December 30, 2020 - The Russian Direct Investment Fund and the Central de Abastecimiento y Suministros de Salud of the Plurinational State of Bolivia announced that supplies to the country have 2.6 million doses of the world's first registered coronavirus vaccine Sputnik V.

December 29, 2020 - The Ministry of Health of the Republic of Belarus, the Ministry of Health of the Russian Federation, and the Russian Direct Investment Fund announced the start of vaccination of Belarus's population with the Sputnik V Russian vaccine against coronavirus. Belarus became the first state after Russia to officially register Sputnik V.

December 29, 2020 - Argentina became the third country worldwide to begin vaccinations with the Sputnik V vaccine outside of clinical studies.

December 29, 2020 - Turkey's health officials announced plans to produce the Sputnik V vaccine domestically.

December 28, 2020 - Hungary's Foreign Minister Peter Szijjarto posted on his Facebook page 'the country has received 6,000 doses of Russia's COVID-19 vaccine.' reported Reuters.

December 26, 2020 - Russian Health Minister Mikhail Murashko announced on the Russia-24 broadcaster that the use of the Sputnik V coronavirus vaccine had been approved for people aged 60 and older. "The Health Ministry approved amendments to the instructions for medical use [of the vaccine]. Thus, citizens over 60 years old can now be vaccinated against the new coronavirus infection."

December 23, 2020 -The Russian Direct Investment Fund announced the Russian vaccine registration against the coronavirus Sputnik V by the Argentinean National Directorate of Medicines, Food and Medical Technologies.

December 21, 2020 - The Russian Direct Investment Fund announced a marketing authorization for the Sputnik V vaccine by the Ministry of Health of the Republic of Belarus. Thus, Belarus became the first foreign state to officially register a vaccine on its territory. Vaccination of volunteers in the Republic of Belarus began on October 1, 2020. As part of a double-blind, randomized, placebo-controlled clinical trial, the Sputnik V vaccine involved 100 people in eight medical institutions selected as research centers.

December 21, 2020 - Russian Direct Investment Fund, N.N. N.F. Gamaleas and the pharmaceutical companies AstraZeneca and R-Pharm announced the signing of an agreement on developing and implementing a clinical research program to assess the immunogenicity and safety of the combined use of one of the components of the Sputnik V vaccine of the Center. The parties also agreed to develop scientific and business relations within the framework of the possibilities of joint use of the Sputnik V vaccine. The AZD1222 vaccine will be studied to more persistent and long-term immunization of a person against a new coronavirus infection. A clinical study of the combination of the AZD1222 vaccine with the adenoviral vector of the Sputnik V vaccine of the 26th serotype will begin shortly. The R-Pharm company will also co-sponsor the study.

December 21, 2020 - The Russian Direct Investment Fund announces the start of production of the world's first registered vaccine against coronavirus Sputnik V in the Republic of Kazakhstan. The vaccine's validation batch has been released today by the Karaganda pharmaceutical complex. The batch will be sent to the developer of the vaccine - NITsEM them. N.F. Gamalei. Karaganda Pharmaceutical Complex is an innovative biotechnological, pharmaceutical enterprise with a full range of necessary equipment, qualified personnel, and international standards.

December 14, 2020 - According to the Protocol of Phase III clinical trials of the Sputnik V vaccine, its intermediate efficacy is calculated at three statistically significant representative control points - upon reaching 20, 39, and 78 cases of new coronavirus infection among subjects in both the placebo group and in the group that received the vaccine. As a result of the Data analysis at the first checkpoint (20 cases of the disease), the estimated vaccine efficiency was 92%, at the second checkpoint (39 cases of the disease) - 91.4%. Based on the data obtained to date from the N.I. N.F. Gamalei will prepare a report used to submit documents for the accelerated registration of the Sputnik V vaccine in various countries.

December 11, 2020 - After receiving results on the Russian vaccine's high efficiency "Sputnik V," the Russian Direct Investment Fund, and the N.F. Gamaleya Research Center, on November 23, 2020, made a proposal to AstraZeneca on the use of 1 of the 2 components (human adenoviral vectors) of the Russian Sputnik V vaccine in clinical trials of the AstraZeneca vaccine. AstraZeneca has accepted the RDIF proposal and will begin clinical trials of its vaccine combined with the Sputnik V adenoviral vector of the 26th serotype by the end of 2020.

December 10, 2020 - The Russian Direct Investment Fund and the Government of Argentina have agreed to supply 10 million doses of Sputnik V vaccine to the country.

December 8, 2020 - Russian organizations announced the cosmonaut squad of the V.I. Yu.A. Gagarin and the Cosmonaut Training Center staff interacting with them would be vaccinated. In the future, other employees of the Center and key enterprises of the State Corporation Roscosmos will have the opportunity to protect themselves from SARS-CoV-2 coronavirus infection.

December 8, 2020 - The Director-General of the Russian Direct Investment Fund Kirill Dmitriev, Director of the N.N. N.F. Gamalei Alexander Gintsburg and the head of the Opposition Platform's political council - For Life party, deputy of the Verkhovna Rada of Ukraine Viktor Medvedchuk held a meeting, during which they discussed the possibility of technological transfer and launch of production in Ukraine of the Sputnik V vaccine.

December 4, 2020 - The Russian Direct Investment Fund and the Ministry of Health of the Republic of Kazakhstan announced a cooperation agreement for the registration procedure and the Sputnik V vaccine production and distribution. After receiving Kazakhstan's regulatory authorities' approval, technology transfer will be carried out. The substance's supply to produce at least 2 million doses of the Sputnik V vaccine in the country.

December 4, 2020 - The Russian Federation's capital city of Moscow's mayor reported 'in the first five hours, 5,000 people signed up for the vaccination - teachers, doctors, social workers, those who today most of all risk their health and lives.'

December 2, 2020 - Russian Health Minister Mikhail Murashko said more than 100,000 people had already been vaccinated against COVID-19, as Moscow presented its Sputnik V vaccine to the United Nations over a video link.

December 1, 2020 - Dr. Reddy’s Laboratories Ltd., based in Hyderabad, and the Russian Direct Investment Fund announced they had commenced adaptive phase 2/3 clinical trials for Sputnik V vaccine in India after receiving the necessary clearance from the Central Drugs Laboratory, Kasauli, India. This will be a multicenter and randomized controlled study, including a safety and immunogenicity study. G V Prasad, Co-chairman and Managing Director, Dr. Reddy’s Laboratories said in a press release: “We are working towards making the vaccine available with a combination of import and indigenous production model.”

November 27, 2020 - HYDERABAD based Hetero Labs has joined RDIF to manufacture over 100 million doses of the Sputnik V vaccine in India during 2021.

November 24, 2020 - Article published by 'The developers of Russia’s Sputnik V vaccine today reported 91.4% efficacy from a second interim analysis of more than 18,000 people, bolstering a claim the team made on 11 November with scant evidence. Whereas the initial report rested on a mere 20 cases of COVID-19, with no details on how they were split between vaccinated and placebo groups, the new analysis is based on 39 cases total, eight among the vaccinated group versus 31 in the much smaller placebo arm.'

November 24, 2020 - N.N. N.F. The Gamaleis of the Ministry of Health of the Russian Federation and the Russian Direct Investment Fund announced the positive results of the second interim analysis of Phase III data of the largest double-blind, randomized placebo-controlled clinical post-marketing clinical trial of the Sputnik V coronavirus vaccine in Russian history with the participation of 40,000 volunteers.

November 17, 2020 - The Russian Direct Investment Fund announced a survey of more than 12 thousand respondents in 11 countries about their attitude to vaccination against coronavirus infection. According to the survey, 73% of respondents are ready to be vaccinated against coronavirus.

November 13, 2020 - The Russian Direct Investment Fund and GL Rapha, one of South Korea's leading biotechnology companies, announced an agreement to manufacture in the country more than 150 million doses of the world's first registered vaccine against coronavirus Sputnik V. The parties intend to start production in December of this year and begin deliveries of the vaccine for export in January 2021. More than 150 million doses of the Sputnik V vaccine produced in South Korea will enter the world market.

November 12, 2020 - Hungary's foreign affairs and trade minister Peter Szijjarto announced on national TV that Budapest would receive a Sputnik V sample within a week-and-a-half for laboratory testing. Clinical trials and licensing begin in December 2020, and depending on the results, Hungary will begin to procure the vaccine in January 2021.

November 11, 2020 - Reuters reported Russia’s Sputnik V vaccine is 92% effective at protecting people from COVID-19. 'The uniqueness of the Russian vaccine lies in the use of two different vectors based on the human adenovirus, which allows for a stronger and longer-term immune response as a result of the second immunization.' Alexander Gintsburg, director of the Gamaleya Institute, which developed the vaccine, said the interim results demonstrated that Sputnik V was effective and vaccinations would be rolled out in Russia in the coming weeks.

November 9, 2020 - The Russian Direct Investment Fund and the N.F. The Gamaleis announced an international social media campaign that will provide social media users with the latest and most reliable Russian vaccine information. The campaign uses the #SputnikV hashtag.

October 30, 2020 - Russian Direct Investment Fund, União Química Farmacêutica Nacional, and the Government of Parana's State announce the preliminary submission of a set of documents for a Russian registration vaccine to the Brazilian National Sanitary Inspection Agency. The documents were sent on October 29, 2020.

October 29, 2020 - Dr. Reddy’s Laboratories announced its partnership with the Biotechnology Industry Research Assistance Council, Department of Biotechnology, Government of India, for advisory support on the Sputnik V vaccine's clinical trials in India.

October 27, 2020 - Russian application for WHO prequalification of the Sputnik V vaccine was first since the start of applications.

October 26, 2020 - About 19,000 people have been administered the first component of the Sputnik V vaccine in Moscow and the Moscow Region, about 6,500 of whom have already received the second component, Director of the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry that developed the vaccine, Alexander Gintsburg said in an interview with the Russia-24 TV channel. The vaccination against coronavirus infection with the Russian drug Sputnik V is tolerated without side effects by 85% of those vaccinated.

October 17, 2020 - Russian Direct Investment Fund and Dr. Reddy's Laboratories Ltd (Dr. Reddy's), one of the leading global pharmaceutical companies, has been approved by the Controller General of Medicines of India to conduct Phase 2-3 clinical trials of Sputnik V vaccine in India. The country will conduct multicenter, randomized controlled trials, including safety and immunogenicity trials.

October 14, 2020 - According to a statement: '13,000 of our citizens, volunteers, are already participating in them, and, as you know, the vaccine has already arrived in the constituent entities of the Russian Federation, albeit not in large quantities, but it has already arrived.'

October 12, 2020 - The Russian Direct Investment Fund (RDIF) announced the approval by the Ministry of Health and Prevention of the UAE to conduct Phase III clinical trials of the Sputnik V vaccine. The clinical trials will be overseen by the Abu Dhabi Department of Health and the UAE Ministry of Health and Prevention. The Abu Dhabi Health Services Company, a state-owned Abu Dhabi hospital management company, will process medical protocols.

October 2, 2020 - In a video posted on YouTube, the Russian Federation's capital city of Moscow stated: 'Moscow could receive bulk shipments of Russia’s coronavirus vaccine by the end of 2020 while the vaccine continues to undergo final clinical trials. Around 6,000 volunteers and 600 medics have been inoculated with the Sputnik V vaccine in the Russian capital as part of post-registration, double-blind trials.

October 2, 2020 - The Russian Direct Investment Fund announced the Sputnik V vaccine's first batch to Venezuela's Bolivarian Republic. Vaccination of volunteers in Venezuela will begin in the coming days as part of double-blind, randomized, placebo-controlled clinical trials of the Sputnik V vaccine.

October 1, 2020 - The Lancet published an article: Sputnik V's arrival.

September 30, 2020 - The Russian Direct Investment Fund and Pharco, one of the leading pharmaceutical groups in Egypt (acting through its key operational subsidiary – Biogeneric Pharma), have agreed to secure the supply of 25 million doses of the Sputnik V vaccine to Egypt. 

September 29, 2020 - The Russian Direct Investment Fund and one of the leading pharmaceutical distributors in Nepal, Trinity Pharmaceuticals, have agreed to supply 25 million doses of the Sputnik V vaccine based on a well-studied human adenoviral vectors platform.

September 25, 2020 - The Russian Direct Investment Fund said it is in talks with several countries, including Iran, about the possibility of locally-producing the Sputnik-V vaccine to reduce the number of coronavirus infections.

September 22, 2020 - The Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry said it is developing a coronavirus vaccine study protocol for cancer patients.

September 18, 2020 - The Lancet published 'Safety and efficacy of the Russian COVID-19 vaccine: more information needed,' and the related reply.

September 16, 2020 - The Russian Direct Investment Fund and Dr. Reddy’s Laboratories Ltd. have agreed to cooperate on clinical trials and distribute the Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply Dr. Reddy’s 100 million vaccine doses. Deliveries could begin in late 2020, subject to completion of successful trials and registration of the vaccine by India's regulatory authorities.

September 16, 2020 - The Russian Direct Investment Fund announced discussions with the Republic of Korea on the possibility of production of the Russian Sputnik V vaccine. The negotiations are at their final stage.

September 15, 2020 - Researchers highlight ‘questionable’ data in Russian coronavirus vaccine trial results.

September 11, 2020 - The Russian Direct Investment Fund and the Health Secretariat of the Brazilian state of Bahia signed a cooperation agreement to supply Brazil with up to 50 million doses of the Russian Sputnik V vaccine, beginning in November 2020, subject to Brazilian government regulatory approval. The agreement will also allow the vaccine to be shipped throughout Brazil in the future.

September 9, 2020 - The Russian Direct Investment Fund and the Landsteiner Scientific pharmaceutical company announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico's country.

September 7, 2020 - Russia's Health Ministry Mikhail Murashko stated, 'The first batch of Sputnik V vaccine has been produced for civilian circulation,' reported the Tass news agency. Previously, Minister Murashko explained that civilian production at this stage 'meant vaccination of citizens from the risk groups, namely teachers and doctors, would be carried out simultaneously with post-registration clinical trials.'

September 4, 2020 - The Lancet study: Safety and immunogenicity of a rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomized phase 1/2 studies from Russia.

September 4, 2020 - The technology institute for the Brazilian state of Paraná has agreed to produce Russia’s “Sputnik-V” COVID-19 vaccine, said on Friday it plans to conduct phase III trials on 10,000 volunteers in Brazil at the start of 2021.

September 2, 2020 - Employees of the National Research Center for Epidemiology and Microbiology were vaccinated against COVID-19, the director of the institution, Alexander Ginsburg, told RIA Novosti. According to Gunzburg, the participants in this stage will be closely monitored by doctors, and they will not be hospitalized. Still, they will take all the necessary tests before, after, and during the research.

August 26, 2020 - The Russian Direct Investment Fund, the Government of Moscow, and the Gamaleya National Research Center of Epidemiology and Microbiology announce the start of a post-registration clinical trial of a coronavirus vaccine in Moscow. Forty thousand people will take part in the program.

August 16, 2020 - Sputnik V's developer said the 3rd stage of trials could be called mass vaccination. The trials will be carried out in the Moscow Region, and some 20,000 - 30,000 people will get the vaccine.

August 15, 2020 - Russia announced that it had produced its first batch coronavirus vaccine.

August 11, 2020 - The Russian Federation's President Putin said his daughter was inoculated with a new Russian coronavirus vaccine.


August 8, 2020 - Special video report on the Russian vaccine against COVID-19 07.08.2020, Russia-24.

August 6, 2020 - Russia is planning a mass vaccination campaign in October, and the vaccine will be first given to doctors and teachers.

August 4, 2020 - Video interview of RDIF CEO Kirill Dmitriev with the BBC.

August 1, 2020 - Clinical trials of a coronavirus vaccine developed by the Gamaleya Scientific Research Institute of Epidemiology and Microbiology are over, Russian Health Minister Mikhail Murashko told reporters.

July 19, 2020 - "Russia may be one of the first to produce a vaccine against the backdrop of the billions that are being invested by all the pharma companies working on it,” said Kirill Dmitriev, the chief executive of the Russian Direct Investment Fund, which previously signed a deal with AstraZeneca to manufacture the University of Oxford’s Covid-19 vaccine at R-Pharm, one of the largest pharmaceutical companies in Russia. 

July 16, 2020 - Russia plans to produce 30 million doses of an experimental COVID-19 vaccine domestically this year. With the potential to manufacture a further 170 million abroad, its sovereign wealth fund's head told Reuters.

July 13, 2020 - The Gamalei center's head Alexander Gintsburg told the TASS news agency that he hopes the vaccine will “enter civil circulation” on Aug. 12-14. He added that he hopes private companies would begin mass production by September. “The research has been completed, and it proved that the vaccine is safe,” Yelena Smolyarchuk, the head of Sechenov University’s clinical research center, told TASS of its trial.

July 12, 2020 - Russia's Sechenov University Announced Successfully Completing Clinical Trials of World's 1st COVID-19 Vaccine. Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical, and Vector-Borne Diseases at Sechenov University, said that this stage of the clinical study's objective was to show the vaccine’s safety for human health, which was successfully done.

July 10, 2020 - The Russian Ministry of Defense announced that it started the final stage of the Coronavirus vaccine clinical trials, run by the Gamalei National Research Center for Epidemiology and Microbiology. These trials began on June 18th, when nine volunteers received 1 component of the vaccine. On June 23th, the vaccine was given to 20 other volunteers who will receive the booster vaccination.

July 7, 2020 - Volunteers who tested a vaccine against the coronavirus  2-weeks ago at Burdenko military hospital feel well and have not experienced any side effects, the Russian Defense Ministry told reporters.

June 11, 2020 - Hit Hard by Coronavirus, Russia Joins Global Race for a Vaccine.

June 10, 2020 - RDIF has supported developing a Russian COVID-19 vaccine scheduled to commence clinical trials by mid-June 2020 and enter production by the fall.

June 4, 2020 - Russia plans to start clinical testing of a coronavirus vaccine on paid volunteers from the general public.

May 29, 2020 - Alexander Gintsburg of Moscow's Gamaleya research institute said last week he had taken a dose of a so-called viral vector vaccine that he hopes will complete clinical trials by the end of the summer.

May 22, 2020 - Russian developers of a coronavirus vaccine have developed immunity to the infection after self-administering it.

Sputnik V Vaccine Clinical Trials

A list of relevant clinical studies is published by Sputnik V vaccine.

On October 17, 2020, RDIF stated the Sputnik V vaccine (Gam-COVID-Vac) is undergoing post-registration clinical trials on 40,000 volunteers in Russia. Sputnik V phase 3 studies are ongoing in Belarus, Venezuela, and the United Arab Emirates.

Clinical Trial NCT04530396: Phase 3 Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 (RESIST) - Last Update Posted: October 27, 2020. Randomized, double-blind (blinded for the trial subject and the study physician), placebo-controlled, multi-center clinical trial in the parallel assignment of efficacy, immunogenicity, and safety Gam-COVID-Vac combined vector vaccine against the SARS-CoV-2-induced coronavirus infection in adults in the SARS-СoV-2 infection prophylactic treatment.

Clinical Trial NCT04436471 - An open two-stage non-randomized Phase 1/2 study with the participation of (38) healthy volunteers. This clinical trial is an open study of the safety, tolerability, and immunogenicity of the drug "Gam-COVID-Vac "solution for intramuscular administration, with healthy volunteers' participation. Last updated on August 12, 2020.